Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.
About
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023.
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240605867852/en/
Investor Contact:
ir@mirumpharma.com
Media Contact:
media@mirumpharma.com
Source: